Implant not recommended in UK, but to be launched in European market

December 12, 2012

The fluocinolone acetonide intravitreal implant (Iluvien, Alimera) has not met the UK’s cost-effectiveness thresholds for treating DME. Alimera has, however, signed an agreement with Quintiles for the implant’s European launch.

Related Content:

News